Espen Johnsen, Chairman

Chairman of the board of directors since 2018

Johnsen is a serial entrepreneur and has a long track record of building successful businesses.  He has broad experience in turning around ailing businesses operating in fast changing and competitive environment, he is actively managing several successful investment portfolios and holds several board positions. Johnsen joined Lytix Biopharma as a shareholder already in 2004 and has followed the company closely.

Gert W. Munthe

Board member since 2014 (Chairman of the board of directors 2015-2018)

Munthe is the founder and Chairman of the Board at Herkules Capital - a leading Nordic private equity player, and he was Chairman of Pronova Biopharma 2004-2013. Munthe has more than 20 years’ experience as a senior executive from both Norwegian and international business. He is former CEO of Alpharma (listed on the NYSE), NetCom and Nycomed Imaging, and he has extensive board experience. Munthe is through his company North Murray the second largest shareholder in Lytix Biopharma.

Debasish F. Roychowdhury

Board member since 2015

Roychowdhury is a recognized leader in the pharmaceutical industry. He is an oncologist with an extensive background in R&D, regulatory affairs and commercial operations, and serves in senior advisory roles for biotechnology companies. From 2009 to 2013, Roychowdhury was Senior Vice President and Head of the Global Oncology Division at Sanofi. Prior to that, he was Vice President and head of Clinical Development at GlaxoSmithKline. He has served as CMO (Chief Medical Officer) for Ra Pharmaceuticals and Seragon Pharmaceuticals. During his tenure in industry, he has been involved in the approval of nine new drugs, several IND filings and supplementary approvals.

Bernt Endrerud

Board member in 2009-2011 and again from 2018

Endrerud is an active innovator and investor. He has established and led several successful businesses and has more than 30 years of experience as a business owner and developer. Endrerud is the owner of Care Holding AS, which is one of the main shareholders of Lytix Biopharma.